SAT-050 Other hormone defficiencies and side effects IN a cohort of adults IN TREATMENT WITH a biosimilar HUMAN GROWTH HORMONE

Abstract Disclosure: E. Venegas moreno: None. A. Jimenez sanchez: None. P. Remon-Ruiz: None. M. Dios Fuentes: None. A. Soto: None. GOAL • To describe other hormone deficiencies and adverse events in a long-lasting cohort of 53 adults under growth hormone (GH) treatment. MATERIALS & METHODS • Transversal study. • Variables were retrospectively collected from the digital health record of the Virgen del Rocío University Hospital in August 2023. • Numerical variables are expressed as mean (standard deviation). Statistical significance was designated as a p-value < 0.05. • Elders defined as ≥ 65 years old. • IGF-1 reference values from our hormone laboratory: /div> Results: • 53 patients under treatment, 7 elders. • 49.35 (19.68) years old. • 22 (41.51%) men, 31 (58.49%) women. • 51 patients had hormonal deficits: - 43 (81.13%) LH/FSH. - 39 (73.58%) TSH. - 37 (69.81%) ACTH. - 10 (18.87%) AVP. /div> p-value = 0.043 /div> p-value = 0.037 /div> p-value = 0.042 /div> p-value = 0.035 • 16.18 (5.39) years in treatment. • 2 incident side effects (3.77%): 1 headache (continued), 1 dizziness (discontinued). • 12 incident benign tumors during treatment in 10 patients. /div> • 3 incident benign tumors before treatment in 3 patients. /div> • 4 incident neoplasms during treatment in 4 patients. /div> • Incident neoplasms before treatment: 0. • IGF-1 levels during treatment if: a. No tumor or neoplasms: 143.80 (53.75) ng/mL b. Tumor: 144.00 (40.83) ng/mL c. Neoplasm: 129.25 (49.28) ng/mL • In ANOVA analysis, we found no differences between groups regarding the variable "tumor" concerning IGF-1 (p-value=0.863) or age (p-value=0.813). • Age at the first tumor: 38.73 (17.98) years, at 9.93 (13.22) years under treatment. ConclusionS: • Pituitary tumors had the most co-secretory deficits. • A very low proportion of the sample developed side effects due to a biosimilar GH. • The number of neoplasms under treatment was low and comprised by skin cancers. • The development of tumors and neoplasms under treatment was not related to IGF-1 levels. Presentation: Saturday, July 12, 2025